Robatumumab (Sch 717454), an anti-human insulin-like growth factor receptor-1 (IGF-1R) antibody, exhibits anti-tumor and anti-proliferative effects on cancer cells. It is applicable in research concerning osteosarcoma and Ewing sarcoma [1] [2].